Table 4. Effect of perindopril on muscle performance based on genotype.
| DD | ID/II | |||||
|---|---|---|---|---|---|---|
| perindopril | No perindopril | P value | perindopril | No perindopril | P value | |
| n | 15 | 17 | 30 | 37 | ||
| f/m | 5/10 | 8/9 | 17/13 | 22/15 | ||
| SPPB baseline | 8 (6, 9) | 7 (6, 8) | 0.635 | 8 (5, 9) | 7 (5, 9) | 0.896 |
| SPPB 12 months | 9 (5, 10) | 9 (6, 9) | 0.710 | 8 (4, 9) | 8 (6, 9) | 0.246 |
| Change in SPPB | 0 (-1, 2) | 1 (-1, 2) | 0.602 | 0 (-2, 1) | 1 (0, 2) | 0.017 |
| Proportionate upper limb muscle mass at 12 months | 1.01 (0.94, 1.05) | 1.01 (0.97, 1.05) | 0.821 | 1.03 (0.98, 1.07) | 1.00 (0.96, 1.04) | 0.303 |
| Proportionate lower limb muscle mass at 12 months | 1.00 (0.99, 1.03) | 1.01 (0.99, 1.05) | 0.545 | 1.01 (0.95, 1.05) | 0.99 (0.96, 1.02) | 0.692 |
| Proportionate grip strength at 12 months | 0.97 (0.90, 1.19) | 1.04 (0.92, 1.32) | 0.423 | 1.07 ± 0.33 | 1.01 (0.93, 1.11) | 0.898 |
| Proportionate QMVC at 12 months | 1.21 (0.97, 1.67) | 1.19 (1.10,1.57) | 0.667 | 1.15 (0.90, 1.38) | 0.96 (0.76, 1.27) | 0.217 |
SPPB: Short Physical Performance Battery score: QMVC: Quadriceps Maximal Voluntary Contraction. Data are presented as median (inter quartile range) and the significance of differences was determined by Mann Whitney U test